v3.26.3
Summary of Significant Accounting Policies (Details)
$ in Millions
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
Segment
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Sep. 30, 2026
TWD ($)
Dec. 31, 2025
TWD ($)
Summary of Significant Accounting Policies [Line Items]              
Cash limit     $ 250,000        
Cash excess of FDIC limit     $ 265,521    
Cash and cash equivalents 11,294   11,294   681,480    
Restricted cash     645,505 [1]    
Provision credit loss     616,452   614,470    
Non employee stock based compensation expenses 845,607 $ 1,663,985 2,140,022 $ 2,395,103      
Stock-based compensation, expense 845,607 1,136,217 $ 1,886,022 2,756,603 [2]      
Number of reportable segments | Segment     1        
Other receivables         760,000    
Revenues [2]      
Total consideration     $ 2,216,926        
Due to related parties   1,236,996   1,236,996      
Description of CODM     The CODM uses revenue and net income before provisions for income tax to assess segment performance and allocate resources, including determining operating budgets and capital allocations.        
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]     Chief Executive Officer        
Restricted Cash [Member]              
Summary of Significant Accounting Policies [Line Items]              
Restricted cash     645,505   $ 20.3
ForSeeCon [Member]              
Summary of Significant Accounting Policies [Line Items]              
Other related parties 760,000   760,000        
Other receivables         200,000    
Revenue recognized   200,000          
Due to related parties 200,000 [3] 200,000 200,000 [3] 200,000 270,000 [3]    
ForSeeCon [Member] | Licensing Agreement [Member]              
Summary of Significant Accounting Policies [Line Items]              
Revenue recognized   200,000          
BioFirst Corporation [Member]              
Summary of Significant Accounting Policies [Line Items]              
Other receivables 760,000   760,000        
OncoX [Member]              
Summary of Significant Accounting Policies [Line Items]              
Other receivables         560,000    
Revenue recognized   595,950          
Revenues       795,950      
Total consideration       35,950      
Due to related parties 560,000 [3] 560,000 560,000 [3] 560,000 595,404 [3]    
OncoX [Member] | Licensing Agreement [Member]              
Summary of Significant Accounting Policies [Line Items]              
Revenue recognized   560,000          
Total consideration       35,950      
BioFirst [Member] | Licensing Agreement [Member]              
Summary of Significant Accounting Policies [Line Items]              
Revenue recognized   760,000          
Taiwan Central Deposit Insurance Corporation [Member]              
Summary of Significant Accounting Policies [Line Items]              
Cash investments limit 95,400   95,400     $ 3.0  
Non-employee Consulting Services [Member]              
Summary of Significant Accounting Policies [Line Items]              
Credit loss expenses          
Non employee stock based compensation expenses 504,425 686,217 1,729,667 2,044,103      
Total director, officer, and employee [Member]              
Summary of Significant Accounting Policies [Line Items]              
Stock-based compensation, reversal $ 341,182   $ 156,355        
Stock-based compensation, expense   $ 450,000   $ 712,500      
[1] Refer to Error Correction in Note 3.
[2] Refer to Restatement of statements of operations for the nine months ended September 30, 2025 in Note 3
[3] As of December 31, 2025, the funds received from ForSeeCon ($200,000) and OncoX ($595,950, of which $546 was paid for then-existing receivables) were initially designated for their payments of licensing fees. In the financial statements as of December 31, 2025, the Company offset payables to ForSeeCon ($200,000) and OncoX ($560,000) with receivables from BioFirst in the amount of $760,000. Upon further review, management determined that these funds did not meet the fund-raising covenant requirements under licensing agreement, recognizing them instead as payables to ForSeeCon and OncoX.

In August 2026, the Company identified this as an accounting error as it did not meet the two-party rule or establish an enforceable right for setoff under ASC 210-20-45. They should have been presented on gross basis. The correction increases Due from related parties and Due to related parties equally by $760,000 at each period end, with corresponding increases in current assets, total assets, current liabilities, and total liabilities. The correction has no effect on revenue, net loss, EPS, equity, cash flows, or working capital. In consideration of ASC 250, SAB 99 and SAB 108, management concluded that the error was not material to the previously issued financial statements, individually or in the aggregate. The Company revised the prior-period information presented herein. The table below shows the effect on payables to related-party and as reported, adjustment, and revised as of December 31, 2025.